Landscape → Immunology

Ulcerative Colitis Clinical Trial Landscape

Data updated: May 20, 2026

522 clinical trials tracked since 2008

Ulcerative Colitis is being studied across 522 clinical trials registered since 2008, with 146 programs currently active. The competitive pipeline includes 36 active Phase 3 trials, 72 active Phase 2 trials, and 25 active Phase 1 trials. Top industry sponsors include Takeda, Eli Lilly, AbbVie.

146 active

522 total (since 2008)

Phase 1 Active

128 total

Phase 2 Active

232 total

Phase 3 Active

128 total

Phase 4 Active

80 total

Top Industry Sponsors

Sorted by active Active Done Failed

Takeda 9 13 3

Eli Lilly 8 4 1

AbbVie 6 9 2

Roche 5 10 5

Pfizer 3 9 4

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT07071519 RECRUITING

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

AbbVie n=120

NCT06937086 RECRUITING

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Eli Lilly and Company n=350

NCT03950232 ACTIVE NOT RECRUITING

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Pfizer n=896

NCT04033445 ACTIVE NOT RECRUITING

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development, LLC n=1,064

NCT05442567 RECRUITING

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Takeda n=240

+ 123 more Phase 3 trials — see full database below

Ulcerative Colitis — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Takeda

Eli Lilly

AbbVie

Roche

Pfizer

Sanofi

Abivax S.A.

Bausch Health Americas, Inc.

Gilead

Merck

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

187

51-200

190

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Takeda 9 13 3

Eli Lilly 8 4 1

AbbVie 6 9 2

Roche 5 10 5

Pfizer 3 9 4

Sanofi 3 0 2

Abivax S.A. 2 6 0

Bausch Health Americas, Inc. 2 6 0

Gilead 2 3 2

Merck 2 3 0

AltruBio Inc. 2 0 1

Alfasigma S.p.A. 2 0 0

Johnson & Johnson 1 0 1

Mage Biologics 1 1 0

Athos Therapeutics Inc 1 1 0

NCT07071519 RECRUITING

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

AbbVie n=120

NCT06937086 RECRUITING

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Eli Lilly and Company n=350

NCT03950232 ACTIVE NOT RECRUITING

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Pfizer n=896

NCT04033445 ACTIVE NOT RECRUITING

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development, LLC n=1,064

NCT05442567 RECRUITING

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Takeda n=240

NCT06100289 RECRUITING

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Takeda n=70

NCT06588855 RECRUITING

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Hoffmann-La Roche n=350

NCT07185009 RECRUITING

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Sanofi n=671

NCT07184996 RECRUITING

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Sanofi n=980

NCT07158242 RECRUITING

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Hoffmann-La Roche n=100

NCT03519945 ACTIVE NOT RECRUITING

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Eli Lilly and Company n=1,058

NCT04844606 RECRUITING

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Eli Lilly and Company n=150

NCT06589986 ACTIVE NOT RECRUITING

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Hoffmann-La Roche n=400

NCT06880744 RECRUITING

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

AbbVie n=530

NCT06052059 ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Merck Sharp & Dohme LLC n=1,020

NCT05784246 RECRUITING

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Eli Lilly and Company n=60

NCT04624230 ACTIVE NOT RECRUITING

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Pfizer n=118

NCT03843385 RECRUITING

Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis

Andreas Stallmach n=129

NCT06865417 RECRUITING

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Alfasigma S.p.A. n=80

NCT03398135 ACTIVE NOT RECRUITING

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

AbbVie n=1,242

NCT03483246 ACTIVE NOT RECRUITING

Impact of Fecal Microbiota Transplantation in Ulcerative Colitis

Assistance Publique - Hôpitaux de Paris n=150

NCT03006068 ACTIVE NOT RECRUITING

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

AbbVie n=950

NCT05782907 ACTIVE NOT RECRUITING

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

AbbVie n=122

NCT03221036 RECRUITING

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Takeda n=402

NCT06405087 RECRUITING

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Takeda n=70

NCT05767021 ACTIVE NOT RECRUITING

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Eli Lilly and Company n=172

NCT05535946 ACTIVE NOT RECRUITING

ABTECT - Maintenance

Abivax S.A. n=1,116

NCT07177118 NOT YET RECRUITING

Risankizumab for Fibrostenotic Crohn's Disease Treatment

First Affiliated Hospital of Wenzhou Medical University n=260

NCT07154784 ENROLLING BY INVITATION

Long-term Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

Seoul National University Hospital n=30

NCT04738942 ACTIVE NOT RECRUITING

A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Takeda n=57

NCT05771155 ACTIVE NOT RECRUITING

Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®

Polpharma Biologics S.A. n=750

NCT02914535 ACTIVE NOT RECRUITING

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Alfasigma S.p.A. n=1,173

NCT06488625 RECRUITING

Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients with Mild to Moderately Active Ulcerative Colitis

University Hospital Schleswig-Holstein n=459

NCT06614387 NOT YET RECRUITING

Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab

JAROSLAW KIERKUS n=60

NCT06604273 RECRUITING

Unravelling Intestinal Fibrosis in Ulcerative Colitis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=10

NCT03804931 RECRUITING

Fecal Microbiota Transplantation for Ulcerative Colitis

Guangzhou First People's Hospital n=120

NCT03524092 COMPLETED

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Eli Lilly and Company n=1,328

NCT03724175 TERMINATED

The Role of Secondary Bile Acids in Intestinal Inflammation

Stanford University n=2

NCT01585155 COMPLETED

Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

Tanabe Pharma Corporation n=21

NCT02531126 COMPLETED

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Celgene n=877

NCT06570772 TERMINATED

Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio

Alvotech Swiss AG n=301

NCT04883840 TERMINATED

Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis

Universitaire Ziekenhuizen KU Leuven n=177

NCT05507203 COMPLETED

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Abivax S.A. n=639

NCT05507216 COMPLETED

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Abivax S.A. n=636

NCT02632175 COMPLETED

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

AbbVie n=59

NCT05316220 WITHDRAWN

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

AbbVie

NCT03518086 COMPLETED

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Eli Lilly and Company n=1,281

NCT05644665 TERMINATED

A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Bristol-Myers Squibb n=131

NCT04505410 COMPLETED

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

University of Miami n=32

NCT03398148 COMPLETED

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

AbbVie n=1,558

NCT05194007 COMPLETED

Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease

Mohammed Bin Rashid University of Medicine and Health Sciences n=13

NCT02118584 TERMINATED

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Hoffmann-La Roche n=1,822

NCT05479058 TERMINATED

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

Galapagos NV n=22

NCT04060303 COMPLETED

ENhanced Recovery in CHildren Undergoing Surgery

Northwestern University n=599

NCT04223479 COMPLETED

Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan

University of Jordan n=30

NCT03283085 COMPLETED

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Shire n=557

NCT05104229 WITHDRAWN

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

Stefan Holubar MD MS FACS, FASCRS

NCT04064697 TERMINATED

Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy

Centre Hospitalier Universitaire de Saint Etienne n=6

NCT04985968 TERMINATED

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

InDex Pharmaceuticals n=171

NCT04706793 COMPLETED

Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

Pfizer n=42

NCT04205643 COMPLETED

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

Celltrion n=548

NCT03996369 COMPLETED

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Arena Pharmaceuticals n=354

NCT03945188 COMPLETED

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Arena Pharmaceuticals n=433

NCT03758443 TERMINATED

Efficacy & Safety of TD-1473 in Ulcerative Colitis

Theravance Biopharma n=239

NCT03920254 TERMINATED

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Theravance Biopharma n=46

NCT02819635 COMPLETED

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

AbbVie n=1,302

NCT00790933 COMPLETED

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

Takeda n=2,243

NCT03653026 COMPLETED

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

AbbVie n=522

NCT03290781 COMPLETED

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

Shire n=366

NCT02136069 COMPLETED

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors

Hoffmann-La Roche n=397

NCT02522780 COMPLETED

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

Ferring Pharmaceuticals n=276

NCT02277223 WITHDRAWN

Curcumin in Pediatric Ulcerative Colitis

Schneider Children's Medical Center, Israel

NCT01470612 COMPLETED

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Pfizer n=944

NCT02435992 COMPLETED

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Celgene n=1,012

NCT02665845 COMPLETED

Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).

Centre Hospitalier Universitaire de Saint Etienne n=160

NCT02100696 COMPLETED

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

Hoffmann-La Roche n=609

NCT02163759 COMPLETED

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Hoffmann-La Roche n=358

NCT02171429 COMPLETED

Hoffmann-La Roche n=358

NCT03259334 TERMINATED

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Shire n=380

NCT02093663 COMPLETED

Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis

Shire n=107

NCT04469062 WITHDRAWN

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

Eli Lilly and Company

NCT03259308 TERMINATED

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Shire n=279

NCT02914522 COMPLETED

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

Gilead Sciences n=1,351

NCT02522767 COMPLETED

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

Ferring Pharmaceuticals n=228

NCT02065622 COMPLETED

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

AbbVie n=952

NCT01340872 COMPLETED

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)

Shield Therapeutics n=128

NCT01496053 COMPLETED

Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

Oslo University Hospital n=100

NCT02065557 COMPLETED

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

AbbVie n=101

NCT02954159 TERMINATED

Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC

Medical College of Wisconsin n=4

NCT00801723 COMPLETED

(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

Bausch Health Americas, Inc. n=123

NCT02280629 COMPLETED

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)

Dr. Falk Pharma GmbH n=150

NCT01882764 TERMINATED

HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis

Hutchison Medipharma Limited n=66

NCT01805791 TERMINATED

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Hutchison Medipharma Limited n=201

NCT00679432 COMPLETED

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Bausch Health Americas, Inc. n=510

NCT00679380 COMPLETED

(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Bausch Health Americas, Inc. n=514

NCT00620126 COMPLETED

The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis

University of Maryland, Baltimore n=47

NCT01692743 COMPLETED

Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)

University of Maryland, Baltimore n=348

NCT01532648 COMPLETED

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

Bausch Health Americas, Inc. n=510

NCT02039505 COMPLETED

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

Takeda n=292

NCT02520284 TERMINATED

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Gilead Sciences n=165

NCT01903252 COMPLETED

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

Tillotts Pharma AG n=817

NCT01550965 COMPLETED

A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting

AbbVie (prior sponsor, Abbott) n=463

NCT02144350 TERMINATED

Hyperbaric Oxygen for Ulcerative Colitis

Dartmouth-Hitchcock Medical Center n=18

NCT02368717 COMPLETED

An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase

Ferring Pharmaceuticals n=281

NCT01059344 COMPLETED

Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis

Tillotts Pharma AG n=281

NCT02849951 TERMINATED

A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

Prometheus Laboratories n=25

NCT01458574 COMPLETED

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis

Pfizer n=593

NCT02142725 TERMINATED

Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis

Dr. Falk Pharma GmbH n=468

NCT01567956 TERMINATED

Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study

sigma-tau i.f.r. S.p.A. n=150

NCT01538251 TERMINATED

Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis

sigma-tau i.f.r. S.p.A. n=147

NCT02266849 TERMINATED

Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study

Odense University Hospital n=12

NCT01465763 COMPLETED

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Pfizer n=614

NCT01745770 COMPLETED

TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)

Dr. Falk Pharma GmbH n=306

NCT01458951 COMPLETED

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Pfizer n=547

NCT01320436 COMPLETED

Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis

Sheba Medical Center n=50

NCT01670240 COMPLETED

Adalimumab in the Treatment of Chronic Pouchitis

Odense University Hospital n=13

NCT01551290 COMPLETED

A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis

Xian-Janssen Pharmaceutical Ltd. n=99

NCT00737789 COMPLETED

Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.

Ferring Pharmaceuticals n=206

NCT00853099 COMPLETED

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

AbbVie (prior sponsor, Abbott) n=274

NCT00783718 COMPLETED

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Millennium Pharmaceuticals, Inc. n=895

NCT01193894 COMPLETED

Trial on Profermin and Fresubin in Ulcerative Colitis

Nordisk Rebalance A/S n=73

NCT01257399 COMPLETED

Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

Tillotts Pharma AG n=251

NCT01257386 COMPLETED

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

Tillotts Pharma AG n=251

NCT00810030 COMPLETED

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR

Vifor Pharma n=484

NCT00720538 COMPLETED

Thalidomide in Pediatric Inflammatory Bowel Diseases.

IRCCS Burlo Garofolo n=84

NCT01004185 TERMINATED

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

Warner Chilcott n=39

NCT00713310 COMPLETED

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

Warner Chilcott n=83

NCT01045018 COMPLETED

A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis

EMET Pharmaceuticals, LLC

NCT07415044 RECRUITING

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Eli Lilly and Company

NCT07186101 RECRUITING

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Eli Lilly and Company

NCT05287126 RECRUITING

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Pfizer

NCT06254950 ACTIVE NOT RECRUITING

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Takeda

NCT05327790 RECRUITING

LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

University of Alberta

NCT05202990 NOT YET RECRUITING

Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis

Assistance Publique - Hôpitaux de Paris

NCT06619990 RECRUITING

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Xencor, Inc.

NCT06109441 ACTIVE NOT RECRUITING

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

AltruBio Inc.

NCT07012395 RECRUITING

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Spyre Therapeutics, Inc.

NCT06979336 RECRUITING

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Genentech, Inc.

NCT05177835 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Abivax S.A.

NCT06975722 RECRUITING

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

Sanofi

NCT07463183 RECRUITING

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Merck Sharp & Dohme LLC

NCT06598943 RECRUITING

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Eli Lilly and Company

NCT07535489 NOT YET RECRUITING

Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

Nanjing Immunophage Biotech Co., Ltd

NCT06693908 RECRUITING

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

Genentech, Inc.

NCT07223424 RECRUITING

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Diwakar Davar

NCT07374471 RECRUITING

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

Mage Biologics

NCT06290934 ACTIVE NOT RECRUITING

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

Gilead Sciences

NCT07513181 NOT YET RECRUITING

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

Athos Therapeutics Inc

NCT05486104 ACTIVE NOT RECRUITING

Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

Ganzhou Hemay Pharmaceutical Co., Ltd

NCT07507513 NOT YET RECRUITING

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

NCT07265570 RECRUITING

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

InSilico Medicine Hong Kong Limited

NCT07501078 NOT YET RECRUITING

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

Muhammad N Aslam, MD

NCT07427017 RECRUITING

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

Northwestern University

NCT06071312 RECRUITING

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

NCT05739864 RECRUITING

Superdonor FMT in Patients With Ulcerative Colitis

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

NCT07300553 RECRUITING

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

Assistance Publique - Hôpitaux de Paris

NCT07113522 RECRUITING

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Mirador Therapeutics, Inc.

NCT04373473 RECRUITING

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

The University of Texas Health Science Center, Houston

NCT06636656 ACTIVE NOT RECRUITING

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Boehringer Ingelheim

NCT07335055 RECRUITING

A Study for HSK47388 in Participants With Ulcerative Colitis

Haisco Pharmaceutical Group Co., Ltd.

NCT06029972 RECRUITING

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

Gilead Sciences

NCT06850727 RECRUITING

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

Odyssey Therapeutics

NCT07232576 RECRUITING

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT07229950 RECRUITING

A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease

Shandong Suncadia Medicine Co., Ltd.

NCT07333716 RECRUITING

Desloratadine in Patients With Ulcerative Colitis

Tanta University

NCT04767984 ACTIVE NOT RECRUITING

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Northwestern University

NCT03869905 ACTIVE NOT RECRUITING

Aquamin® as an Adjuvant Intervention for Ulcerative Colitis

Muhammad N Aslam, MD

NCT07258641 NOT YET RECRUITING

Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease

University Medical Center Groningen

NCT07341282 NOT YET RECRUITING

Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

McMaster University

NCT04276740 ACTIVE NOT RECRUITING

MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis

University of Edinburgh

NCT06764615 RECRUITING

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

Takeda

NCT07297069 NOT YET RECRUITING

Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial

Asian Institute of Gastroenterology, India

NCT07295834 NOT YET RECRUITING

Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial

Imperial College London

NCT04924270 RECRUITING

Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases

Odense University Hospital

NCT07064707 RECRUITING

Rupatadine in Patients With Ulcerative Colitis

Alexandria University

NCT06420492 RECRUITING

Study of Novel Therapeutics for Acute Remedy of Colitis

Brigham and Women's Hospital

NCT06257875 ACTIVE NOT RECRUITING

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

AbbVie

NCT06127043 ACTIVE NOT RECRUITING

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

AnaptysBio, Inc.

NCT07080034 RECRUITING

Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis

Biocad

NCT07083193 RECRUITING

A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis

Accro Bioscience (Suzhou) Limited

NCT06993974 RECRUITING

Nitazoxanide in Patients With Ulcerative Colitis

Alexandria University

NCT07035041 RECRUITING

A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis

InventisBio Co., Ltd

NCT03847467 RECRUITING

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

Children's Hospital Medical Center, Cincinnati

NCT06420375 RECRUITING

Treatment of UC With Novel Therapeutics

Brigham and Women's Hospital

NCT06453317 RECRUITING

Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis

Medical University of Lodz

NCT06867042 NOT YET RECRUITING

Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment

Jina Pharmaceuticals Inc.

NCT06606808 RECRUITING

Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

University Medical Center Groningen

NCT05466890 ACTIVE NOT RECRUITING

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

Palatin Technologies, Inc

NCT06213857 RECRUITING

Beneficial Effect of Silymarin in Ulcerative Colitis

Tanta University

NCT05119140 ACTIVE NOT RECRUITING

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

Icahn School of Medicine at Mount Sinai

NCT06725017 NOT YET RECRUITING

A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis

Guangzhou Zhiyi Biotechnology Co., Ltd.

NCT06667934 NOT YET RECRUITING

Clinical Trial of Zuoqing SAN in Treating Ulcerative Colitis

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

NCT06604260 RECRUITING

FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients

Dalia Lartey

NCT06421818 RECRUITING

Effect and Mechanism of Baitouweng Decoction for Large Intestine Damp-heat Syndrome of Ulcerative Colitis

The Second Hospital of Nanjing Medical University

NCT04925973 ACTIVE NOT RECRUITING

Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

McMaster University

NCT03196427 COMPLETED

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Takeda

NCT04023396 COMPLETED

Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

Abivax S.A.

NCT04543994 TERMINATED

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

The Cleveland Clinic

NCT05998213 COMPLETED

Transfer of Feces in Ulcerative Colitis 2

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT06137183 TERMINATED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Genentech, Inc.

NCT07370220 COMPLETED

Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients

Benha University

NCT04987307 TERMINATED

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Amgen

NCT05539625 WITHDRAWN

Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis

University of Edinburgh

NCT05570006 COMPLETED

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

AbbVie

NCT05370885 TERMINATED

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Vedanta Biosciences, Inc.

NCT04090411 COMPLETED

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Hoffmann-La Roche

NCT03760003 COMPLETED

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Abivax S.A.

NCT01671956 TERMINATED

Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis

Alexion Pharmaceuticals, Inc.

NCT05377580 COMPLETED

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Innovent Biologics (Suzhou) Co. Ltd.

NCT05672199 TERMINATED

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Amgen

NCT04857112 COMPLETED

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

Bausch Health Americas, Inc.

NCT05770609 COMPLETED

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Shanghai Pharmaceuticals Holding Co., Ltd

NCT02895100 TERMINATED

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

Protagonist Therapeutics, Inc.

NCT04996797 COMPLETED

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT04607837 COMPLETED

Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

Pfizer

NCT05058417 WITHDRAWN

Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

Sadat City University

NCT05785715 TERMINATED

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

AbbVie

NCT05019742 TERMINATED

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Shanghai Pharma Biotherapeutics USA Inc.

NCT05118919 COMPLETED

A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis

BioGaia Pharma AB

NCT04882007 COMPLETED

Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis

OSE Immunotherapeutics

NCT03368118 COMPLETED

Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

Abivax S.A.

NCT04855799 COMPLETED

GI Permeability Change in Response to Aquamin®

James Varani

NCT03998488 COMPLETED

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

Weill Medical College of Cornell University

NCT06398808 COMPLETED

A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

Zydus Lifesciences Limited

NCT05061446 COMPLETED

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Pfizer

NCT04877990 COMPLETED

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

Bristol-Myers Squibb

NCT03093259 COMPLETED

ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Abivax S.A.

NCT04700449 COMPLETED

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Connect Biopharm LLC

NCT02647866 COMPLETED

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Kyowa Kirin, Inc.

NCT04259060 WITHDRAWN

Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission

Joshua Korzenik

NCT04004611 COMPLETED

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

Eli Lilly and Company

NCT03934216 COMPLETED

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Bristol-Myers Squibb

NCT03341962 TERMINATED

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

Immunic AG

NCT03977480 TERMINATED

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

Tianjin Hemay Pharmaceutical Co., Ltd

NCT03298022 TERMINATED

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

AltruBio Inc.

NCT04277546 TERMINATED

Open-label Extension Study of Brazikumab in Ulcerative Colitis

AstraZeneca

NCT03616821 TERMINATED

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

AstraZeneca

NCT02330653 COMPLETED

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Stacy A. Kahn

NCT03650413 TERMINATED

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Genentech, Inc.

NCT04596293 COMPLETED

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Bridge Biotherapeutics, Inc.

NCT04898348 WITHDRAWN

A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis

KoBioLabs

NCT04556383 TERMINATED

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

GB004, Inc.

NCT03861143 COMPLETED

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

NImmune Biopharma

NCT03675477 COMPLETED

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

Reistone Biopharma Company Limited

NCT04202211 WITHDRAWN

FMT for Remission of Active Ulcerative Colitis in Adults

University of British Columbia

NCT04504383 COMPLETED

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Protagonist Therapeutics, Inc.

NCT03720002 COMPLETED

HF2 Therapy in the Treatment of Active Ulcerative Colitis

Sheba Medical Center

NCT03558152 COMPLETED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Genentech, Inc.

NCT03695185 COMPLETED

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

AbbVie

NCT04577794 COMPLETED

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

Galapagos NV

NCT04353791 COMPLETED

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis

Oncostellae S.L

NCT02393248 TERMINATED

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

NCT03521232 TERMINATED

A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis

Entero Therapeutics

NCT04102852 COMPLETED

Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients

San Giovanni Addolorata Hospital

NCT05372939 COMPLETED

Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

Applied Molecular Transport

NCT04130919 TERMINATED

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

Gilead Sciences

NCT03759041 TERMINATED

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics, Inc.

NCT02958865 COMPLETED

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Pfizer

NCT03986996 TERMINATED

Antimicrobial Therapy for Ulcerative Colitis (UC)

Wolfson Medical Center

NCT05121402 WITHDRAWN

Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis

TLL Pharmaceutical, LLC

NCT03565939 COMPLETED

Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO)

ParaTech A/S

NCT03800420 TERMINATED

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Bridge Biotherapeutics, Inc.

NCT03182166 COMPLETED

Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization

Centre Hospitalier Universitaire de Saint Etienne

NCT03773952 COMPLETED

Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients

Palobiofarma SL

NCT03269695 TERMINATED

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

Pfizer

NCT01090154 COMPLETED

Study of Cimzia for the Treatment of Ulcerative Colitis

University of Washington

NCT02536404 COMPLETED

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Arena Pharmaceuticals

NCT04096573 WITHDRAWN

Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis

LG Chem

NCT03104036 COMPLETED

Faecal Bacteriotherapy for Ulcerative Colitis

Institute for Clinical and Experimental Medicine

NCT01988506 COMPLETED

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Assistance Publique - Hôpitaux de Paris

NCT01716039 TERMINATED

Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Alimentiv Inc.

NCT01620255 COMPLETED

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Shire

NCT01771809 COMPLETED

Long-Term Safety Of PF-00547659 In Ulcerative Colitis

Shire

NCT01647516 COMPLETED

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

Celgene

NCT03574948 COMPLETED

5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores

University Hospital, Ghent

NCT04000139 COMPLETED

Anthocyanin Rich Extract (ACRE) in Patients With Ulcerative Colitis

University of Zurich

NCT03378921 COMPLETED

Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis

Helsinki University Central Hospital

NCT02447302 COMPLETED

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Arena Pharmaceuticals

NCT00790478 TERMINATED

Melatonin and Ulcerative Colitis: A Pilot Clinical Trial

Emory University

NCT02606032 COMPLETED

Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis

Hamilton Health Sciences Corporation

NCT03178669 COMPLETED

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

InDex Pharmaceuticals

NCT03235752 COMPLETED

Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

I-Mab Biopharma HongKong Limited

NCT00572585 COMPLETED

Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

Novartis Pharmaceuticals

NCT03138655 COMPLETED

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Takeda

NCT04209556 WITHDRAWN

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Pfizer

NCT03546868 COMPLETED

Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease

Asan Foundation

NCT03794765 COMPLETED

Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis

Post Graduate Institute of Medical Education and Research, Chandigarh

NCT04348890 WITHDRAWN

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

ReveraGen BioPharma, Inc.

NCT00659802 COMPLETED

Phase II Study of HMPL-004 in Patients With Ulcerative Colitis

Hutchison Medipharma Limited

NCT04434872 TERMINATED

Fecal Microbiota Transplantation as a Treatment for Ulcerative Colitis

Tel-Aviv Sourasky Medical Center

NCT02589665 COMPLETED

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Eli Lilly and Company

NCT02289417 COMPLETED

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

Amgen

NCT01375179 TERMINATED

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Novartis Pharmaceuticals

NCT01461317 COMPLETED

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

Genentech, Inc.

NCT03627052 WITHDRAWN

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Incyte Corporation

NCT00805285 TERMINATED

The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

University of Maryland, Baltimore

NCT04032652 TERMINATED

Use of Rectal Dialysis Technique to Measure Rectal 5-ASA Levels in Healthy Volunteers Receiving Asacol

Endeavor Health

NCT03018054 COMPLETED

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

EA Pharma Co., Ltd.

NCT01959165 COMPLETED

MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients

AstraZeneca

NCT01694485 COMPLETED

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Amgen

NCT01456052 COMPLETED

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

Lexicon Pharmaceuticals

NCT02049502 COMPLETED

FMT in Ulcerative Colitis-Associated Pouchitis

Virginia O. Shaffer

NCT01287195 COMPLETED

Oral OKT3 for the Treatment of Active Ulcerative Colitis

Brigham and Women's Hospital

NCT01520324 COMPLETED

Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy

Cosmo Technologies Ltd

NCT02808390 TERMINATED

Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC

PPM Services S.A.

NCT03711006 COMPLETED

The Effect of Fecal Microbiota Transplantation in Ulcerative Colitis

Alice Højer Christensen

NCT01562314 COMPLETED

A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)

GW Research Ltd

NCT01149707 COMPLETED

Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis

PurGenesis Technologies Inc.

NCT01393405 COMPLETED

Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis

University of North Carolina, Chapel Hill

NCT00718094 COMPLETED

Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

University of Louisville

NCT02426372 COMPLETED

Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis

Qu Biologics Inc.

NCT02888379 COMPLETED

Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

Topivert Pharma Ltd

NCT01296841 COMPLETED

Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care

VA Palo Alto Health Care System

NCT00895336 WITHDRAWN

Lactobacillus GG in Pediatric Ulcerative Colitis (UC)

Children's Hospital Medical Center, Cincinnati

NCT02227342 COMPLETED

Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis

University of Alberta

NCT01896635 COMPLETED

Faecal Microbiota Transplantation in Ulcerative Colitis

The University of New South Wales

NCT01612039 COMPLETED

Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis

Telsar Pharma Inc.

NCT02913508 WITHDRAWN

Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

Takeda

NCT01336465 COMPLETED

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Genentech, Inc.

NCT01659138 TERMINATED

Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

Sanofi

NCT01861249 TERMINATED

Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

Sanofi

NCT01111292 TERMINATED

Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia

National Cancer Institute (NCI)

NCT01482884 COMPLETED

Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis

AstraZeneca

NCT02337608 COMPLETED

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis

Galapagos NV

NCT00656890 COMPLETED

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis

Bristol-Myers Squibb

NCT01837615 COMPLETED

Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT01846026 WITHDRAWN

Ulcerative Colitis and Vitamin D Supplementation

University Hospital of North Norway

NCT00751933 TERMINATED

Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis

Haukeland University Hospital

NCT01839214 COMPLETED

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

Vascular Biogenics Ltd. operating as VBL Therapeutics

NCT01545908 COMPLETED

Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis

Hamilton Health Sciences Corporation

NCT01650038 COMPLETED

Transplantation of Faeces in Ulcerative Colitis; Restoring Nature's Homeostasis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT01810185 WITHDRAWN

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

Santa Barbara Cottage Hospital

NCT01706159 TERMINATED

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Novo Nordisk A/S

NCT00616434 COMPLETED

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Biogen

NCT01506362 COMPLETED

Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis

BioLineRx, Ltd.

NCT01829321 COMPLETED

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis

Galapagos NV

NCT00787202 COMPLETED

A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

Pfizer

NCT01037322 COMPLETED

Cannabidiol for Inflammatory Bowel Disease

Meir Medical Center

NCT01033305 COMPLETED

Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)

Sigmoid Pharma

NCT00628433 COMPLETED

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

Harbor Therapeutics

NCT01245465 COMPLETED

Profermin® in Active Ulcerative Colitis

Nordisk Rebalance A/S

NCT00808977 COMPLETED

A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis

Palau Pharma S.L.U.

NCT00729872 COMPLETED

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis

ActoGeniX N.V.

NCT03816345 RECRUITING

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

NCT07401680 RECRUITING

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

University of Alberta

NCT07350577 ACTIVE NOT RECRUITING

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

AltruBio Inc.

NCT07505030 NOT YET RECRUITING

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants

LyncBio Therapeutics Co., Ltd.

NCT02636517 ENROLLING BY INVITATION

Fecal Microbiome Transplant

Judith Kelsen

NCT07416383 NOT YET RECRUITING

Safety and Efficiency of the Universal CNK-UT009 in Difficult-to-treat Inflammatory Bowel Disease Patients

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT05666960 RECRUITING

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

Rise Therapeutics LLC

NCT04312113 ACTIVE NOT RECRUITING

Angiographic Delivery of AD-MSC for Ulcerative Colitis

Mayo Clinic

NCT05852574 ACTIVE NOT RECRUITING

CP101 for the Treatment of Ulcerative Colitis

Brigham and Women's Hospital

NCT07177157 NOT YET RECRUITING

The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients

Terry Ponich

NCT06749795 NOT YET RECRUITING

LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)

Liveome Inc.

NCT06627556 RECRUITING

A Study of Single and Multiple Ascending Doses of H021 in Healthy Participants

Jiangsu Carephar Pharmaceutical Co., Ltd.

NCT05786404 RECRUITING

Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

The University of Texas Health Science Center, Houston

NCT05218850 RECRUITING

The Use of Butyrate Therapy in Pediatric Ulcerative Colitis

Children's Hospital Los Angeles

NCT06681389 COMPLETED

A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis

NIBEC Co., Ltd.

NCT05578508 WITHDRAWN

Stem Cells for the Treatment of Pouchitis

The Cleveland Clinic

NCT04114292 COMPLETED

TUDCA as a Therapy for Ulcerative Colitis (UC)

Washington University School of Medicine

NCT05549323 TERMINATED

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Pfizer

NCT06582264 COMPLETED

A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

Microbiotica Ltd

NCT07029971 TERMINATED

A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis

Vial Australia Pty Ltd

NCT06363383 COMPLETED

A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants

Mage Biologics

NCT04924114 COMPLETED

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Merck Sharp & Dohme LLC

NCT03358706 TERMINATED

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Janssen Research & Development, LLC

NCT06663605 COMPLETED

Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.

Palisade Bio

NCT03948919 COMPLETED

Fecal Transplant for Ulcerative Colitis

University of Minnesota

NCT06206811 COMPLETED

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

Odyssey Therapeutics

NCT05176366 TERMINATED

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

Direct Biologics, LLC

NCT03478956 TERMINATED

A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease

Hoffmann-La Roche

NCT05975047 COMPLETED

A Study of LIV001 in Healthy Subjects and Those with Mild-to-Moderate Active Ulcerative Colitis (UC)

Liveome Inc.

NCT06080048 COMPLETED

A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis

Sorriso Pharmaceuticals, Inc.

NCT05587673 COMPLETED

High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)

Stanford University

NCT06260267 WITHDRAWN

A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

Ferring Pharmaceuticals

NCT04254783 COMPLETED

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

AbbVie

NCT05807971 COMPLETED

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects

Athos Therapeutics Inc

NCT06281704 COMPLETED

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Akeso

NCT03169894 TERMINATED

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Avalo Therapeutics, Inc.

NCT03943550 TERMINATED

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

Hoffmann-La Roche

NCT05084261 COMPLETED

An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

Adiso Therapeutics

NCT04691232 COMPLETED

Autologous Ex Vivo Expanded Regulatory T Cells in Ulcerative Colitis

University of Erlangen-Nürnberg Medical School

NCT04828031 COMPLETED

Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease

Stanford University

NCT02985593 COMPLETED

A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis

Kyowa Kirin Co., Ltd.

NCT02200445 COMPLETED

Low Dose IL-2 for Ulcerative Colitis

Scott B. Snapper, MD PHD

NCT05844592 COMPLETED

First in Human, Single Ascending Dose Study

Innovo Therapeutics, Inc.

NCT04862741 COMPLETED

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Landos Biopharma Inc.

NCT03656627 TERMINATED

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Alliance Foundation Trials, LLC.

NCT05088369 COMPLETED

Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

Syneos Health

NCT04458805 COMPLETED

Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers

Landos Biopharma Inc.

NCT04478825 TERMINATED

Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Bridge Biotherapeutics, Inc.

NCT02818686 COMPLETED

TD-1473 for Active Ulcerative Colitis (UC)

Theravance Biopharma

NCT02365480 COMPLETED

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

National Cancer Institute (NCI)

NCT03482648 COMPLETED

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Bridge Biotherapeutics, Inc.

NCT01130844 COMPLETED

Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis

Shire

NCT01387594 COMPLETED

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Shire

NCT03768219 TERMINATED

Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Aptevo Therapeutics

NCT03832400 COMPLETED

Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC)

NuBiyota

NCT03006809 COMPLETED

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis

Najwa Elnachef

NCT03923478 TERMINATED

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

Assembly Biosciences

NCT02108821 COMPLETED

Fecal Microbiota Transplantation in Pediatric Patients

Children's Mercy Hospital Kansas City

NCT01831427 COMPLETED

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Gilead Sciences

NCT04360343 COMPLETED

Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy Subjects

LG Chem

NCT03103412 COMPLETED

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Theravance Biopharma

NCT02442960 COMPLETED

Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis

Stanford University

NCT02749630 COMPLETED

A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)

Genentech, Inc.

NCT04224857 COMPLETED

SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101

Applied Molecular Transport

NCT02883452 COMPLETED

A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis

Celltrion

NCT04018599 COMPLETED

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Fresenius Kabi SwissBioSim GmbH

NCT03849599 COMPLETED

A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis

Provention Bio, Inc.

NCT03860896 COMPLETED

GB004 in Adult Subjects With Active Ulcerative Colitis

GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

NCT03597971 TERMINATED

HMPL004-6599 Phase I Dose-escalating Study

Nutrition Science Partners Limited

NCT02618187 COMPLETED

A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics, Inc.

NCT02487238 COMPLETED

Pediatric FEcal Microbiota Transplant for Ulcerative Colitis

McMaster Children's Hospital

NCT03038711 COMPLETED

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

Bristol-Myers Squibb

NCT03705117 COMPLETED

Open-label V565 Target Engagement Study

VHsquared Ltd.

NCT03071081 COMPLETED

Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects

Topivert Pharma Ltd

NCT03327558 COMPLETED

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

Bausch Health Americas, Inc.

NCT02516384 COMPLETED

Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)

Weill Medical College of Cornell University

NCT01929941 TERMINATED

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Incyte Corporation

NCT02864264 TERMINATED

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Bristol-Myers Squibb

NCT01757964 COMPLETED

Bacteriotherapy in Pediatric Inflammatory Bowel Disease

David Suskind

NCT02463045 COMPLETED

Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects

Topivert Pharma Ltd

NCT02267694 COMPLETED

Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis

UConn Health

NCT02818543 COMPLETED

Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis

Lycera Corp.

NCT00694980 COMPLETED

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

Genentech, Inc.

NCT02058524 TERMINATED

A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis

University of Chicago

NCT01947101 COMPLETED

Fecal Microbiota Transplantation (FMT) for Treatment of Ulcerative Colitis in Children

Baylor College of Medicine

NCT01971814 COMPLETED

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

University of California, San Francisco

NCT01290042 COMPLETED

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Amgen

NCT02306798 COMPLETED

TP0502-B-Pharmaco-Scintigraphic-Study

Tillotts Pharma AG

NCT02306785 COMPLETED

TP0502-Pharmaco-Scintigraphic-Study and Amendment

Tillotts Pharma AG

NCT02306772 COMPLETED

TP0501 - Pharmaco-Scintigraphic-Study

Tillotts Pharma AG

NCT02209987 COMPLETED

Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults

Gilead Sciences

NCT01759056 COMPLETED

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

Avaxia Biologics, Incorporated

NCT01097590 COMPLETED

A Study to Evaluate a Leukapheresis Treatment in Patients With Ulcerative Colitis

IBD Column Therapies International AB

NCT01434576 WITHDRAWN

Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis

Human Genome Sciences Inc.

NCT01164904 TERMINATED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Amgen

NCT01320332 COMPLETED

A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

Telsar Pharma Inc.

NCT01020708 COMPLETED

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

Altheus Therapeutics, Inc.

NCT01149694 COMPLETED

A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers

PurGenesis Technologies Inc.

NCT00889161 COMPLETED

Curcumin in Pediatric Inflammatory Bowel Disease

Seattle Children's Hospital

NCT06581328 RECRUITING

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Takeda

NCT07576452 NOT YET RECRUITING

FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

University Hospital, Clermont-Ferrand

NCT07240649 NOT YET RECRUITING

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

Jay C. Buckey Jr.

NCT06964113 RECRUITING

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Eisai Korea Inc.

NCT07216014 RECRUITING

Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety

Sixth Affiliated Hospital, Sun Yat-sen University

NCT07550673 RECRUITING

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

Xijing Hospital of Digestive Diseases

NCT07546097 RECRUITING

Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）

Yongquan Shi

NCT07502339 NOT YET RECRUITING

Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis

University of California, San Francisco

NCT07248644 NOT YET RECRUITING

Immunosuppressant Discontinuation in Elderly Patients With Ulcerative Colitis And Long-term Remission

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

NCT06095128 RECRUITING

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Takeda

NCT04835506 ACTIVE NOT RECRUITING

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

Beth Israel Deaconess Medical Center

NCT07258771 RECRUITING

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

Berinstein, Jeffrey

NCT07303686 RECRUITING

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT07235904 RECRUITING

Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis

University Hospital Schleswig-Holstein

NCT05976802 NOT YET RECRUITING

Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis

Bausch Health Americas, Inc.

NCT04314375 RECRUITING

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Bausch Health Americas, Inc.

NCT06788340 NOT YET RECRUITING

MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

Odense University Hospital

NCT05481619 RECRUITING

Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT07059130 NOT YET RECRUITING

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

Rubix LS

NCT04743518 RECRUITING

Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis

Centre Hospitalier Universitaire, Amiens

NCT05867329 RECRUITING

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

Berinstein, Jeffrey

NCT05313620 RECRUITING

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

NCT06298461 RECRUITING

Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

University of Manitoba

NCT06625450 NOT YET RECRUITING

TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS

Post Graduate Institute of Medical Education and Research, Chandigarh

NCT06609447 RECRUITING

The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT06113913 RECRUITING

Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

NCT04999241 NOT YET RECRUITING

Combined Application of EEN in the Induction of Remission in PUC

Children's Hospital of Fudan University

NCT04999228 RECRUITING

Top Down Versus Step up in Pediatric Ulcerative Colitis

Children's Hospital of Fudan University

NCT04183608 RECRUITING

A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

NCT05205603 COMPLETED

Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis

Sixth Affiliated Hospital, Sun Yat-sen University

NCT07398586 COMPLETED

The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis

Second Affiliated Hospital of Wenzhou Medical University

NCT05180175 COMPLETED

The Nordic IBD Treatment Strategy Trial

Region Örebro County

NCT06626165 COMPLETED

Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa

Showa Inan General Hospital

NCT03679546 COMPLETED

EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis

Rennes University Hospital

NCT04626947 TERMINATED

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

David Binion, MD

NCT06897150 COMPLETED

Carotegrast Methyl in Ulcerative Colitis

Takayuki Yamamoto

NCT03798691 COMPLETED

Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

University of Wisconsin, Madison

NCT03885713 COMPLETED

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

NCT02921555 TERMINATED

Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

NCT04804540 COMPLETED

A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease

Takeda

NCT05684484 COMPLETED

Role of Roflumilast in Ulcerative Colitis

Tanta University

NCT04231110 COMPLETED

Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis

McMaster University

NCT02770040 COMPLETED

Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis

Austin Health

NCT06188637 WITHDRAWN

Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study

Geert D'Haens

NCT04156984 COMPLETED

Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis

David Drobne

NCT05992142 COMPLETED

ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

NCT02425865 COMPLETED

Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

NCT02425852 COMPLETED

A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

NCT03281304 TERMINATED

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Pfizer

NCT02994836 COMPLETED

GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

NCT02962245 WITHDRAWN

Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis

Xijing Hospital of Digestive Diseases

NCT02345733 COMPLETED

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis

Prof. Arie Levine

NCT01941589 COMPLETED

Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis

Sheba Medical Center

NCT04775732 COMPLETED

Ultra-proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Imelda GI Clinical Research Center

NCT04969679 COMPLETED

Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.

Kangbuk Samsung Hospital

NCT03124121 COMPLETED

Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels

Guy's and St Thomas' NHS Foundation Trust

NCT01124149 COMPLETED

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

Shire

NCT04131322 TERMINATED

Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

NCT03059849 WITHDRAWN

Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD

McMaster University

NCT01536535 COMPLETED

Predicting Response to Standardized Pediatric Colitis Therapy

Connecticut Children's Medical Center

NCT02579733 TERMINATED

Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis

Kyungpook National University Hospital

NCT03237260 WITHDRAWN

An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis

University of Pennsylvania

NCT02155335 COMPLETED

Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)

Merck Sharp & Dohme LLC

NCT02092285 COMPLETED

Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)

Merck Sharp & Dohme LLC

NCT02148640 COMPLETED

The NOR-SWITCH Study

Diakonhjemmet Hospital

NCT01991314 COMPLETED

Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate

Queen Mary University of London

NCT01418131 COMPLETED

Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis

The University of Western Australia

NCT02465385 COMPLETED

Single-dose Linaclotide for Capsule Endoscopy Preparation

University of Virginia

NCT01346826 COMPLETED

Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)

Asan Medical Center

NCT01882426 TERMINATED

Care Path for the Management of Ulcerative Colitis

University of Western Ontario, Canada

NCT01960426 TERMINATED

Evaluation of Health Costs and Resource Utilization

University of Western Ontario, Canada

NCT01201122 COMPLETED

Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis

Wolfson Medical Center

NCT01481142 COMPLETED

Adacolumn in Refractory UC Patients Trial

Otsuka Pharmaceutical Europe Ltd

NCT00702611 TERMINATED

Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

NCT01678911 TERMINATED

Efficacy of Gralise® for Chronic Pelvic Pain

Shirley Ryan AbilityLab

NCT00652145 COMPLETED

Dose Escalation and Remission (DEAR)

James Lewis

NCT01772615 COMPLETED

Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle

Hvidovre University Hospital

NCT01341808 COMPLETED

Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients

Asan Medical Center

NCT01408810 COMPLETED

Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis

Grupo de Estudo da Doença Inflamatória Intestinal

NCT00947674 TERMINATED

A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)

Asahi Kasei Medical Co., Ltd.

Full Ulcerative Colitis Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only